News | February 04, 2025
Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
PAT after MI is Rs. 41 crore which is 162% increase
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Modernization and supply chain diversity drive new growth
Q2 FY25 Total Income was at Rs. 85.4 crore
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Subscribe To Our Newsletter & Stay Updated
